

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 13, 2024

DIH HOLDING US, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-41250
(Commission
File Number)

98-1624542

77 Accord Park Drive; Suite D-1, Norwell, MA
(Address of principal executive offices)

02061
(Zip Code)

Registrant's telephone number, including area code: (617) 871-2101

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock Warrants	DHAI DHAIW	The Nasdaq Stock Market LLC The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure

On March 13, 2024, DIH Holding US, Inc. made available on the Company's website an investor presentation. A copy of the presentation is furnished as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(a)-(b) Financial Statements.

(c) Exhibits.

99.1 [Investor Presentation Dated March 13, 2024](#)

104 Cover Page Interactive Data File (Formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 13, 2024

DIH HOLDING US, INC.

By: /s/ Jason Chen

Name: Jason Chen

Title: Chief Executive Officer and Chairman

DELIVER INSPIRATION & HEALTH



DIH

**DEDICATED TO RESTORING MOBILITY AND
ENHANCING HUMAN PERFORMANCE**

**Investor Presentation
March 2024**

Nasdaq: DHA1



In this presentation, "DIH", "DIH Medical", the "Company", "we", "us" and "our" mean DIH Holding US, Inc. All amounts are in U.S. dollars unless otherwise indicated. The information contained herein does not purport to contain all of the information about the Company. The information contained herein has not been independently verified. No representations or warranties are made or implied with respect to the information contained herein.

This presentation contains forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, including without limitation the successful and timely completion and the commercialization of the products referred to herein. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks and strategies or deliverables stated herein, may involve, but are not limited to, comments with respect to the Company's business or financial objectives, its strategies or future actions, its targets, expectations for financial condition or outlook for operations. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and conditional, are intended to identify forward-looking statements.

Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. These assumptions are considered to be reasonable based on currently available information, but the reader is cautioned that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business. The forward-looking information set forth therein reflects expectations as of the date hereof and is subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Undue reliance should not be placed on forward-looking statements. The forward-looking statements contained in this presentation are expressly qualified by this cautionary statement.

This presentation is not intended to form the basis of any investment decision and there can be no assurance that any transaction will be undertaken or completed in whole or in part. The delivery of this presentation shall not be taken as any form of commitment on the part of the Company or its stockholders to proceed with any transaction, and no offers will subject the Company or its stockholders to any contractual obligations before definitive documentation has been executed. The Company reserves the right at any time without prior notice and without any liability to (i) negotiate with one or more prospective investors in accordance with any timetable and on any terms that the Company may decide, (ii) provide different information or access to information to different prospective investors, (iii) enter into definitive documentation and (iv) terminate the process, including any negotiations with any prospective investor without giving any reasons therefor.

DIH at a glance:

Robotic-enabled movement platform improving the lives of people with disabilities and functional impairments



Improving lives by providing human movement therapy while empowering leading scientists and clinics to study balance and movement disorders through Advanced Technology.





DIH – a Global Solution Provider, has the **broadest portfolio in neuro-rehabilitation and human performance research**, with over 5,000 devices installed.

With an aging population and an increasing number of people living with neurological diseases, hospitals and clinics will be understaffed; **robotic rehabilitation** fills the gap and **helps therapists and patients thrive**.

More intensive, repetition-based therapy, supported by Advanced Technology is shown to have **superior patient outcomes** and can send them home sooner.

Technology solves the supply-demand problem in rehabilitation settings by allowing occupational and physical therapists to work with multiple patients effectively.

Bridging the gap between Clinical and Research applications by enabling and inventing the most advanced technological ways to study and treat balance and movement disorders.



1 HQ
DIH Holding US



5 Commercial Regions
USA, Singapore, Chile, Slovenia, Germany



3 Sites
For R&D and manufacturing in CH, NL and USA



243 Employees
in 9 global locations from 33 nationalities



19
Products
& Systems



4,500+
Devices installed¹



1,500+
Medical device
registrations
in 75 countries



\$55M
FY23² Revenue
12% YoY increase



\$69M
FY23 Sales Orders³
11% YoY increase



1,800
Customer Accounts

¹ Includes clinical and research install base

² FY23 year ending March 2023

³ Signed sales orders represent the pipeline of sales for DIH generated during a prescribed period

Meeting market demands with innovative Advanced Technologies

Health Providers

Research Facilities



Rehabilitation Hospitals



Physical Therapy and Rehab Clinics



Patients

Neurological



- Stroke
- SCI & cerebral palsy
- Parkinson's disease
- Traumatic brain injury

Orthopedic



- Amputation
- Osteoarthritis
- Musculoskeletal disorders

Geriatric & Pediatric



- Aging population with an increased risk of falling and functional impairment
- Pediatric patients with mobility impairments

<p>Research & Human Movement Labs* (“Research Market”)</p>	<p>Rehabilitation Hospitals and Outpatient Clinics (“Hospital and Clinic Market”)</p>																	
	<table border="1"> <tr> <td data-bbox="478 347 718 504"> <p>ARMEO POWER</p> </td> <td data-bbox="718 347 957 504"> <p>ARMEO SPRING / SPRING PRO</p> </td> <td data-bbox="957 347 1197 504"> <p>ARMEO SENSO</p> </td> <td data-bbox="1197 347 1524 504"> <p>ARM & HAND</p> </td> </tr> <tr> <td data-bbox="478 504 718 761"> <p>ERIGO</p> </td> <td data-bbox="718 504 877 761"> <p>LOKOMAT¹</p> </td> <td data-bbox="877 504 1037 761"> <p>SAFEGAIT</p> </td> <td data-bbox="1037 504 1197 761"> <p>RYSEN</p> </td> <td data-bbox="1197 504 1356 761"> <p>ANDAGO</p> </td> <td data-bbox="1356 504 1524 761"> <p>C-MILL²</p> </td> <td data-bbox="1197 504 1524 761"> <p>GAIT & BALANCE</p> </td> </tr> <tr> <td colspan="5" data-bbox="478 761 1524 873"> <p>³ HocoNet</p> </td> <td data-bbox="1197 761 1524 873"> <p>DATA INTEGRATION</p> </td> </tr> </table>	<p>ARMEO POWER</p>	<p>ARMEO SPRING / SPRING PRO</p>	<p>ARMEO SENSO</p>	<p>ARM & HAND</p>	<p>ERIGO</p>	<p>LOKOMAT¹</p>	<p>SAFEGAIT</p>	<p>RYSEN</p>	<p>ANDAGO</p>	<p>C-MILL²</p>	<p>GAIT & BALANCE</p>	<p>³ HocoNet</p>					<p>DATA INTEGRATION</p>
<p>ARMEO POWER</p>	<p>ARMEO SPRING / SPRING PRO</p>	<p>ARMEO SENSO</p>	<p>ARM & HAND</p>															
<p>ERIGO</p>	<p>LOKOMAT¹</p>	<p>SAFEGAIT</p>	<p>RYSEN</p>	<p>ANDAGO</p>	<p>C-MILL²</p>	<p>GAIT & BALANCE</p>												
<p>³ HocoNet</p>					<p>DATA INTEGRATION</p>													

*Motek products are currently being sold by DIH through an exclusive relationship between Motek and DIH

¹ Two product lines available ² Product line consists of three products ³ Prototype available; In development

Aging population

>1B

Members of a growing elderly population, worldwide¹

46%+

of the world's aging population has disabilities²



Increasing neurological disorders and related disabilities

Est. **15%**

of the global population is affected by neurological disorders³

38%+

of stroke survivors were found to have disabilities⁴



Need of care and lack of therapist

Est. **2.4B**

People are currently living with a health condition that may benefit from rehabilitation⁵

1.09

physiotherapists per 1,000 people⁶



Advanced Technology is key to meeting market demands.


¹ WHO: Ageing and Health; <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>
² United Nations: Aging and Disability; <https://www.un.org/development/desa/disabilities/disability-and-ageing.html>
³ <https://pubmed.ncbi.nlm.nih.gov/36902495/>
⁴ NCBI: Causes and Trends of Disabilities in Community-Dwelling Stroke Survivors: A Population-Based Study; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833459/>

⁵ WHO: Rehabilitation; <https://www.who.int/news-room/fact-sheets/detail/rehabilitation#:~:text=Globally%2C%20an%20estimated%202.4%20billion,and%20characteristics%20of%20the%20population.>
⁶ 2020: World Physio: <https://world.physio/sites/default/files/2021-02/AMC2020-Europe.pdf> // WHO: <https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3408>; https://www.theglobeconomy.com/rankings/physiotherapists_per_1000_people/



MMT: Manual Muscle Test for shoulder and/or elbow; MMT 2 for Armeo Senso =with arm weight support

INVESTOR PRESENTATION
CONTINUUM OF CARE FOR LOWER EXTREMITIES REHABILITATION




FAC: Functional Ambulation categories

INTENDED USE

TARGETS ALL ASPECTS OF BALANCE AND LOCOMOTION. THE USE OF VIRTUAL REALITY ENABLES RESEARCHERS TO ASSESS THE SUBJECT'S BEHAVIOR AND INCLUDES SENSORY INPUTS LIKE VISUAL, AUDITORY AND VESTIBULAR.

PROVIDES ANALYSIS AND THERAPY IN CHALLENGING CONDITIONS TO IMPROVE GAIT, WHILE REAL-TIME FEEDBACK ENABLES ANALYSIS AND TRAINING DURING THE SAME SESSION.


ENABLES MULTIPLE SYSTEM ENHANCEMENTS FOR ADDED FUNCTIONALITY OF GAIT-LAB.



CAREN EXTENDED*
Computer Assisted
Rehabilitation Environment



CAREN HIGH END*
Computer Assisted
Rehabilitation Environment



GRAIL*
Gait Real-time Analysis
Interactive Lab



M-GAIT*
Modular Gait Lab

*Motek products are currently being sold by DIH through an exclusive agreement between Motek and DIH

DIH provides a **broad portfolio of devices** and an **extensive range of services**,
to become a **Total Solution partner** for our customers



**BUSINESS MODEL
and PLANNING**

We provide guidelines and support customers in building their rehabilitation project. We find the right solution to match the organizations' needs, space and budget.



**CLINICAL
SERVICES**

To help make the best use of our solutions, we offer **clinical integration consulting and ongoing support**, as well as education and training.



**TECHNICAL
SERVICES**

We provide **technical support and regular maintenance** after installation so customers can maintain **clinical routines without disruption**.



**RESEARCH
SERVICES**

Research drives us forward and our **support and services** help institutions initiate their own research programs.



**MARKETING
SERVICES**

Customers immediately **stand out from other rehabilitation facilities**. With our support we make sure they are seen and heard.




>60

Leading Institutions trust DIH

DIH collaborates with world renowned institutions in rehabilitation and research as reference centers and innovation partners




**LOKOMAT
610**



**CAREN
204***



**ARMEO LINE
217**



**GRAIL &
M-Gait
234***



**ERIGO
60**



**C-Mill
70***

>1,300

Published Research Studies

90%+ peer-reviewed² studies
40+ ongoing studies

¹The Knowledge Platform includes all research articles, conference proceedings, and theses available on our devices and can be accessed via knowledge.hocoma.com

²Reviewed and evaluated by a group of experts in the field before the article is published.

*Motek Products are currently being sold by DIH through an exclusive agreement between Motek and DIH



DIH is uniquely positioned as a leader in rehabilitation-tech and research markets



Leading Technology

Highly recognized premier brands and technologies in our industry, endorsed by leading rehabilitation institutes and opinion leaders



Product Portfolio

Broadest product portfolio in advanced robotics and sophisticated VR-enabled movement systems; most competitors operate in a single product category



Industry Experience

Organizational breadth and depth with significant experience in acquisition integration; key to our growth strategy and differentiation from competitors that are early in their organizational life cycles



Innovation

Sustained innovation capabilities with decades of proven expertise and resources



Tech Partnerships

Platform and core technology (hardware and software) supported by strong partnerships with leading research groups



Network Effect


Strong supporting functions and operational infrastructure that establish a platform network effect which will be difficult to replicate



Commercial Reach

Strong global market coverage with approx. 3-5x more sales volume than competitors


Global Market



- Global solution provider combining innovative robotic and VR technologies with clinical integration and proprietary insights.
- Transformative total solutions provider and consolidator in a fragmented and manual-labor-driven industry.
- Innovative and broad product portfolio, covering the entire continuum of care.
- Strong financial profile with \$55M revenue in FY23, representing 12% year-over-year growth.

¹ "Rehabilitation Robots Market by Product, End user and Geography – Forecast and Analysis (2023 – 2027)" November 2022

Way Forward - Investment Opportunity



¹ Grandview Research, October 14, 2022



Financial Highlights

1H24 Performance


Revenue of **\$27.3M**, an increase of **58% over 1H23**

- 78% devices
- 22% services

Sales Orders¹ of **\$36.5M**, an increase of **15% over 1H23**

- 79% in clinic and research
- 21% in hospital

46% Gross Margin



¹Signed sales orders represent the pipeline of sales for DIH generated during a prescribed period



Jason Chen
Chief Executive Officer and
Chairman of the Board



Lynden Bass
Chief Financial Officer



Dr. Patrick Bruno
Chief Market Officer



Deloitte.





CEO and Chairman of the Board
Jason Chen



Chief Financial Officer
Lynden Bass



Chief Market Officer
Hospital & Clinic
Patrick Bruno



Vice President
Research
Frans Steenbrink



Vice President
Global Customer Success
Marco Albuquerque



Senior Vice President
Sales – EMEA Indirect
Slavko Skafar



Vice President
Global Operations
Walther Geiger



Vice President
FP&A and Commercial Operations
Finance
LaTonya Vincent

**We are proud to improve lives.
Everyday.**

Differentiated technology and intensive training can significantly reduce disabilities

Competitive golfer Mike Jones' world changed when he was involved in a motorcycle accident that claimed his leg. Thanks to advanced rehabilitation robotics and new physical therapy techniques, Mike found what he was looking for to allow him once again to live life his way.



“My life has changed beyond anything I thought possible. Lying in my hospital bed, bandaged and bruised, it would have been inconceivable to think of where I am now. The C-Mill helped make this miracle happen for me.”


Mike Jones
Amputee Patient, Morello Clinic



<https://youtu.be/4ix7zmyWpTM>

Differentiated technology and intensive training can improve quality of lives for pediatric patients

Diagnosed with cerebral palsy with an official statement saying that she would not be able to walk.
Thanks to the intensive rehabilitation including intensive gait training with the Lokomat, Nele can walk now.
She has impressive outcomes and now has more confidence in daily life activities.



“An official statement considered my daughter Nele to be untreatable. Thanks to the intensive training on the Lokomat, Nele can walk right now and has more confidence in daily life activities.”

Mother of Nele Kohlof
CP Patient in Germany



<https://youtu.be/NTRHeuGB890>





“ To facilitate the progression from highly intensive Lokomat robot-aided gait training to training overground for best skill transfer to daily life, we need **tools that are extremely flexible**. The Andago offers that flexibility and ease of use and I like its versatility, which should allow us to optimally prepare our patients for the wide variety of environments and challenges they need to master in everyday activities.”

Prof. Alberto Esquenazi
Chief Medical Officer, MossRehab, USA

“ The CAREN system puts us on the leading edge by enabling us to **safely challenge patients** through different courses in an immersive, realistic virtual environment.”

Dr. Jay Alberts
Vice Chair for Health Technology Enablement
Cleveland Clinic Neurological Institute,
Director of Cleveland Clinic's Concussion Center



“ We're able to get patients walking up to 30, 40 minutes, which is a **massive difference** compared to what we're able to do without the Lokomat. One aspect that I personally like is the fact that the robot and the treadmill change speed according to the effort that the patient is putting in. I found that to be really **beneficial and motivating to the patients**.”

Tamsin Reed
Physiotherapy Clinical Lead, The Wellington Hospital, UK

hocomia.com // motekmedical.com (2018-2022)



“ **Standing up straight and moving forward** one step after another for the first time in 22 years is a special feeling. I'm thankful to the Andago for this. ”

Geni Bissig
Patient with incomplete SCI

“ **My life has changed beyond anything** I thought possible. Lying in my hospital bed, bandaged and bruised, it would have been inconceivable to think of where I am now. **The C-Mill made this miracle happen for me.** ”

Mike Jones
Amputee Patient, Morello Clinic



“ **After Lokomat Training, Carson was just flying!** His mobility was better and he was so much more self-confident. ”

Mother of Carson Rush
CP patient in USA

THANK YOU

For more information contact
investor.relations@dih.com

